. ओषधनिर्माता , चाक्छी परीक्षा - 2092. अव-ब

प्रश्नपुस्तिका क्रमांक BOOKLET No.

2012

Code: RRM

परीमा दि: 30 नून, 2012

200769

प्रश्नपुस्तिका

चाळणी परीक्षा

वेळ : 1 तास

एकूण प्रश्न : 100 एकूण गुण : 100

सूचना

(1) सदर प्रश्नपुस्तिकेत 100 अनिवार्य प्रश्न आहेत. उमेदवारांनी प्रश्नांची उत्तरे लिहिण्यास सुरुवात करण्यापूर्वी या प्रश्नपुस्तिकेत सर्व प्रश्न आहेत किंवा नाहीत याची खात्री करून घ्यावी. असा तसेच अन्य काही दोष आढळल्यास ही प्रश्नपुस्तिका समवेक्षकांकडून लगेच बदलून घ्यावी.

(2) आपला परीक्षा-क्रमांक ह्या चौकोनांत न विसरता बॉलपेनने लिहावा.

- (3) वर छापलेला प्रश्नपुस्तिका क्रमांक तुमच्या उत्तरपित्रकेवर विशिष्ट जागी उत्तरपित्रकेवरील सूचनेप्रमाणे न विसरता नमूद करावा.
- (4) या प्रश्नपुस्तिकेतील प्रत्येक प्रश्नाला 4 पर्यायी उत्तरे सुचिवली असून त्यांना 1, 2, 3 आणि 4 असे क्रमांक दिलेले आहेत. त्या चार उत्तरांपैकी सर्वात योग्य उत्तराचा क्रमांक उत्तरपित्रकेवरील सूचनेप्रमाणे तुमच्या उत्तरपित्रकेवर नमूद करावा. अशा प्रकारे उत्तरपित्रकेवर उत्तरक्रमांक नमूद करताना तो संबंधित प्रश्नक्रमांकासमोर छायांकित करून दर्शविला जाईल याची काळजी घ्यावी. ह्याकिरता फक्त काळ्या शाईचे बॉलपेन वापरावे, पेन्सिल वा शाईचे पेन वापरू नये.
- (5) सर्व प्रश्नांना समान गुण आहेत. यास्तव सर्व प्रश्नांची उत्तरे द्यावीत. घाईमुळे चुका होणार नाहीत याची दक्षता घेऊनच शक्य तितक्या वेगाने प्रश्न सोडवावेत. क्रमाने प्रश्न सोडविणे श्रेयस्कर आहे पण एखादा प्रश्न कठीण वाटल्यास त्यावर वेळ न घालविता पुढील प्रश्नाकडे वळावे. अशा प्रकारे शेवटच्या प्रश्नापर्यंत पोहोचल्यानंतर वेळ शिल्लक राहिल्यास कठीण म्हणून वगळलेल्या प्रश्नांकडे परतणे सोईस्कर ठरेल.
- (6) उत्तरपत्रिकेत एकदा नमूद केलेले उत्तर खोडता येणार नाही. नमूद केलेले उत्तर खोडून नव्याने उत्तर दिल्यास ते तपासले जाणार नाही.
- (7) प्रस्तुत परीक्षेच्या उत्तरपत्रिकांचे मूल्यांकन करताना उमेदवाराच्या उत्तरपत्रिकेतील योग्य उत्तरांनाच गुण दिले जातील. तसेच ''उमेदवाराने वस्तुनिष्ठ बहुपर्यायी स्वरूपाच्या प्रश्नांची अचूक उत्तरेच उत्तरपत्रिकेत नमूद करावीत. अन्यथा त्यांच्या उत्तरपत्रिकेत सोडविलेल्या प्रत्येक चार चुकीच्या उत्तरांसाठी एका प्रश्नाचे गुण वजा करण्यात येतील''.

ताकीद

ह्या प्रश्नपत्रिकेसाठी आयोगाने विहित केलेली वेळ संपेपर्यंत ही प्रश्नपुस्तिका आयोगाची मालमत्ता असून ती परीक्षाकक्षात उमेदवाराला परीक्षेसाठी वापरण्यास देण्यात येत आहे. ही वेळ संपेपर्यंत सदर प्रश्नपुस्तिकेची प्रत/प्रती, किंवा सदर प्रश्नपुस्तिकेतील काही आशय कोणत्याही स्वरूपात प्रत्यक्ष वा अप्रत्यक्षपणे कोणत्याही व्यक्तीस पुरविणे, तसेच प्रसिद्ध करणे हा गुन्हा असून अशी कृती करणाऱ्या व्यक्तीवर शासनाने जारी केलेल्या ''परीक्षांमध्ये होणाऱ्या गैरप्रकारांना प्रतिबंध करण्याबाबतचा अधिनियम-82'' यातील तरतुदीनुसार तसेच प्रचलित कायद्याच्या तरतुदीनुसार कारवाई करण्यात येईल व दोषी व्यक्ती कमाल एक वर्षाच्या कारावासाच्या आणि/किंवा रुपये एक हजार रकमेच्या दंडाच्या शिक्षेस पात्र होईल.

तसेच ह्या प्रश्नपत्रिकेसाठी विहित केलेली वेळ संपण्याआधी ही प्रश्नपुस्तिका अनिधकृतपणे बाळगणे हा सुद्धा गुन्हा असून तसे करणारी व्यक्ती आयोगाच्या कर्मचारीवृंदापैकी, तसेच परीक्षेच्या पर्यवेक्षकीयवृंदापैकी असली तरीही अशा व्यक्तीविरुद्ध उक्त अधिनियमानुसार कारवाई करण्यात येईल व दोषी व्यक्ती शिक्षेस पात्र होईल.

पुढील सूचना प्रश्नपुस्तिकेच्या अंतिम पृष्ठावर पहा

पर्यवेक्षकांच्या सूचनेविना हे सील उघडू नये

RRM

2

Student Bounty.com कच्च्या कामासाठी जागा / SPACE FOR ROUGH WORK

www.StudentBounty.com

- 1. 'Xerogel' refers to
 - (1) Hydrogel

- (2) Dehydrated gel
- (3) Gel containing organic solvent
- (4) Excess water in gel
- 2. Formula to relate doses for children to their age as per Young's rule is given by

(1)
$$\frac{\text{Age in years}}{\text{Age in years} + 20}$$
 = Proportion of adult dose

(2)
$$\frac{\text{Age in years}}{20}$$
 = Proportion of adult dose

(3)
$$\frac{\text{Age in years}}{12}$$
 = Proportion of adult dose

(4)
$$\frac{\text{Age in years}}{\text{Age in years} + 12}$$
 = Proportion of adult dose

- 3. Drugs with low therapeutic index have to be cautiously administered since
 - (1) their median toxic dose is high
 - (2) they are very potent and have low dose
 - (3) difference between effective and toxic levels is less
 - (4) None of the above
- 4. The concentration of dextrose isotonic with blood plasma is
 - (1) 0.9% w/v

(2) 4.5% w/v

(3) 5% w/v

- (4) 0.45% w/v
- **5.** Which of the following is commonly not used for packaging by pharmacists for filling a prescription?
 - (1) Blister pack

- (2) Prescription bottles
- (3) Sifter top containers
- (4) Dropper bottles

SPACE FOR ROUGH WORK

| | - | | • | 35 |
|-----|-------------|---|--------|--------------------------------------|
| 6. | Whi drug | ich of the following is $oldsymbol{not}$ a meth | od for | enhancing transdermal per |
| | (1) | Iontophoresis | (2) | Sonophoresis |
| | (3) | Electrophoresis | (4) | Hydration of skin |
| 7. | Who | en hypotonic solution is injected into | raveno | ously it leads to |
| | (1). | Shrinkage of RBCs | | |
| | (2) | Haemolysis of RBCs | | · |
| | (3) | Neither shrinkage nor haemolysi | s | |
| | (4) | (1) and (2) | | |
| | | t choice as a diluent in this situation Hydrophilic ointment | | Vaseline |
| | (1) | Hydrophilic ointment | (2) | Vaseline |
| | (3) | Lanolin | (4) | Cold cream |
| 9. | Wh | at does Schedule W of Drugs and C | osmeti | cs Act 1940 and Rules 1945 contain ? |
| | (1) | List of drugs which shall be mark | eted u | nder generic name only |
| | (2) | Life period of drugs | | |
| | (3) | Standards for cosmetics | | |
| | (4) | Biological and special products | | |
| 10. | Wh | at does DTAB abbreviate for ? | | |
| | (1) | Drugs Technology Advisory Board | | |
| | (2) | Directorate of Technological Advis | ory Bo | pard |

(3)

Directorate of Technical Advisory Board

Drugs Technical Advisory Board

- Student Bounty.com Aqueous coating systems for water insoluble polymers are commonly prepared 11. form of
 - **(1)** solubilized systems by means of surfactant addition
 - solutions with the aid of cosolvents
 - (3)pseudolatex systems which are colloidal dispersions
 - **(4)** None of the above
- **12.** Computer base PMRs are used for maintaining
 - Patient Medication Records **(1)**
 - Prescriptions of Prescriber (2)
 - Adverse Drug Reaction (3)
 - **Inventory Control (4)**
- Pyrogens which cause a rise in body temperature when injected intravenously are 13. structurally
 - Bacterial phospholipids **(1)**
- Bacterial lipopolysaccharides (2)

(3)Viral DNA

- Bacterial glycosides (4)
- As per Schedule A of Drugs and Cosmetics Act 1940 and Rules 1945, Form 19-B is for
 - Application for licence to sell, stock or exhibit or offer for sale or distribute Homoeopathic medicines
 - Licence to manufacture for sale or for distribution of Homoeopathic (2)medicines
 - Licence to manufacture for sale or for distribution of drugs other than those specified in Schedule C, C(I) & X
 - Certificate of renewal of licence to sell, stock or exhibit or offer for sale or distribute Homoeopathic medicines

SPACE FOR ROUGH WORK

| | | | | 3 |
|-----|-----|---|----------|--|
| RRM | | | 6 | xpressed as to total volume of suspension |
| 15. | The | degree of flocculation of a suspens | ion is e | xpressed as |
| | (1) | Ratio of volume of flocculated sed | iment t | o total volume of suspension |
| | (2) | Ratio of total volume of suspension | n to vo | |
| | (3) | Ratio of sedimentation volume of volume of the suspension when de | | lated suspension to the sedimentation ated |
| | (4) | Sediment volume of flocculated su | ıspensio | on |
| 16. | Сар | oping in tablets occurs due to | | |
| | (1) | Defective dies and punches | (2) | Damp granules |
| | (3) | Excessive fines | (4) | (1) and (3) |
| 17. | Tox | icity at normal doses of Isoniazid is | s likely | to be due to |
| | (1) | Age | (2) | Generic factor |
| | (3) | Disease state | (4) | Renal function |
| 18. | The | Drugs Price Control Order is pass | ed unde | er |
| | (1) | Essential Commodities Act | (2) | Drugs and Cosmetics Act |
| | (3) | Pharmacy Act | (4) | Control of Prices Act |
| 19. | | adverse reaction relatively specific | to the | use of antibiotics belonging to the class |
| | (1) | Ototoxicity | (2) | Occular toxicity |
| | (3) | Hepatotoxicity | (4) | Aplastic anaemia |
| 20. | Wh | ich of the following is a non-absorb | able su | ture ? |
| | (1) | Cat gut | (2) | Reconstituted collagen |
| | (3) | Polyamide | (4) | Kangaroo tendon |

| 4 | | 7 | de |
|--|--|------------------------------------|--|
| | erance to one kind of drug that re ng is known as | sults in t | Reciprocity Cross tolerance |
| (1) | Synergistic dependence | (2) | Reciprocity |
| (3) | Tolerance threshold | (4) | Cross tolerance |
| 22. An as | extension of the normal pharmaco | logical ef | fect of a drug or its metabolite is termed |
| (1) | Type C ADR | (2) | Type D ADR |
| (3) | Type A ADR | (4) | Type B ADR |
| I. | | ·le | |
| | Facing the patient directly. | | |
| I. II. | Leaning forward at a slight ang | le. | |
| | Leaning forward at a slight ang | le. | |
| II. | Leaning forward at a slight ang Nodding and hand gestures. | le. | |
| II. III. | Leaning forward at a slight ang Nodding and hand gestures. | le. (2) | Only I |
| II. III. IV. | Leaning forward at a slight ang Nodding and hand gestures. Blank stares. | | Only I I and IV |
| II. IV. (1) (3) | Leaning forward at a slight ang Nodding and hand gestures. Blank stares. I and II | (2) | I and IV |
| II. IV. (1) (3) | Leaning forward at a slight ang Nodding and hand gestures. Blank stares. I and II I, II and III ootentially life-threatening adverse | (2) (4) drug eff | I and IV |
| II. IV. (1) (3) | Leaning forward at a slight ang Nodding and hand gestures. Blank stares. I and II I, II and III ootentially life-threatening adverse Bronchoconstriction in astham | (2) (4) drug eff | I and IV |
| II. IV. (1) (3) 44. A p (1) | Leaning forward at a slight ang Nodding and hand gestures. Blank stares. I and II I, II and III outentially life-threatening adverse Bronchoconstriction in astham agents | (2) (4) drug eff | I and IV |
| II. IV. (1) (3) 44. A p (1) (2) | Leaning forward at a slight ang Nodding and hand gestures. Blank stares. I and II I, II and III otentially life-threatening adverse Bronchoconstriction in astham agents Osteoporosis caused by steroids | (2) (4) drug eff | I and IV |
| II. IV. (1) (3) (4. A p (1) (2) (3) (4) | Leaning forward at a slight ang Nodding and hand gestures. Blank stares. I and II I, II and III cotentially life-threatening adverse Bronchoconstriction in astham agents Osteoporosis caused by steroids Hirsutism induced by Minoxidil | (2) (4) drug eff atics du | I and IV |
| II. IV. (1) (3) (4. A p (1) (2) (3) (4) | Leaning forward at a slight ang Nodding and hand gestures. Blank stares. I and II I, II and III outentially life-threatening adverse Bronchoconstriction in astham agents Osteoporosis caused by steroids Hirsutism induced by Minoxidil Retinopathy caused by Thiorida. | (2) (4) drug eff atics du | I and IV |

| 26 . | | per I.P., for a batch size of 100 nu duct, minimum numbers recommend | | |
|-------------|-----|---|------------|--|
| | (1) | 10% or 4 numbers, whichever is gr | eater | 13 |
| | (2) | 10% or 6 numbers, whichever is gr | eater | |
| | (3) | 5% or 2 numbers, whichever is gre- | ater | |
| | (4) | 5% or 3 numbers, whichever is gre- | ater —— | |
| 27. | | lition of which of the following t | o a la | arge volume parenteral product is no |
| | (1) | Active pharmaceutical ingredient | (2) | Preservatives |
| | (3) | Buffering agents | (4) | Tonicity adjusters |
| 28. | | ophthalmic solution of a mydriatic d t-order degradation with a rate of 0- | _ | rith a concentration of 5 mg/ml exhibits mg/day. Estimate its half life. |
| | (1) | 693 days | (2) | 1,200 days |
| | (3) | 210 days | (4) | 1,386 days |
| 29. | | ich microbe is used for validati | on of | sterilization by membrane filtration |
| | (1) | Bacillus stearothermophilus | (2) | Pseudomonas aeruginosa |
| | (3) | Serratia marcescens | (4) | Bacillus subtilis |
| 30. | Mor | phine sulphate comes under which | Sched | lule of Drugs and Cosmetics Act ? |
| | (1) | X | (2) | K |
| | (3) | Н | (4) | G . |
| 31. | mı | | | |
| | The | dosage required to produce a desire | d pha | rmacological effect is called |

(3) Effective dose

(4)

Maximum dose

| | | | | 5 |
|-----|------|--|----------------|--|
| Α | | | 9 | ide |
| 32. | In f | orm-fill-seal process the esse | ential materia | al used is |
| | (1) | Aluminium | (2) | Polyacrylate |
| | (3) | Paper-metal composite | (4) | al used is Polyacrylate Polyethylene |
| 33. | Son | ication of liposomal product | may be relat | |
| | (1) | MLV to ULV | (2) | SUV to MLV |
| | (3) | MLV to SUV | (4) | None of the above |
| 34. | | ich of the following plots determined temperature? | would be mo | st helpful in deciding shelf life at a |
| | (1) | Remaining undegraded vs | time | |
| | (2) | Log remaining undegraded | vs time | |
| | (3) | Log rate vs log absolute te | mperature | |
| | (4) | Log rate vs inverse of abso | lute temperat | cure |
| 35. | Whi | ich of the following statemen | nts regarding | polymorphs is true ? |
| | (1) | Polymorphic forms of the formulation | same drug a | re similar and can be substituted in a |
| | (2) | Different polymorphic for diffraction patterns | orms of the | e same drug have identical X-ray |
| | (3) | The metastable polymon dissolution rate | phic forms | will generally result in a higher |
| | | All of the above | | |
| | (4) | All of the above | | |
| 36. | | olution of 1 in 2500 strengtl | n means | |
| 36. | | | n means | 0.4% |

- Student Bounty.com
- **37.** Hixon and Crowell Cube-root law is related to
 - (1) Micro emulsification
 - (2) Drug dissolution
 - (3) Stability of API against hydrolytic degradation
 - (4) Sedimentation in liquids containing more than 10% suspended particles
- **38.** The term 'hydrotrophy' is used to denote
 - (1) water uptake capacity
 - (2) water repulsion capacity
 - (3) increase in aqueous solubility due to presence of large amounts of additives
 - (4) wetting ability
- **39.** Patients on tranylcypromine therapy are in danger of undergoing a hypertensive crisis on consumption of a cheese rich diet due to
 - (1) Interaction of tranylcypromine with calcium in cheese
 - (2) Inhibition of absorption of tranylcypromine by cheese
 - (3) Presence of antioxidant in cheese
 - (4) Tyramine content of cheese
- **40.** An estimate of the water absorption capacity of 100 gms of material as 'water number' is a parameter for evaluation of
 - (1) Hydrogels

(2) Absorption bases

(3) Gelling agents

- (4) Wetting agents
- 41. Autoclavable plasticware for repeated sterilization is best fabricated using
 - (1) Low density polyethylene
- (2) Polystyrene

(3) Polyvinyl chloride

(4) Polypropylene

SPACE FOR ROUGH WORK

| , | | | S. |
|----------------|---|--------------|--|
| Ą | , | 11 | ide |
| 42. Sca | alpels and blades for surgery ma | ay be steri | lized by |
| (1) | Boiling in a water bath | (2) | Dry heat sterilization |
| (3) | Membrane filtration | (4) | Dry heat sterilization Aseptic technique |
| 43. Wh | nich of the following is added as | antioxida | nt in pharmaceutical dosage forms? |
| (1) | Sorbitan monooleate | (2) | Ascorbic acid |
| (3) | Methyl cellulose | (4) | Sodium saccharin |
| 44. Sh | elf life of a pharmaceutical prod | luct is com | puted by |
| (1) | Ficks laws | (2) | Arrhenius equation |
| (3) | Higuchi equation | (4) | Noyes Whitney equation |
| 45. As | per Indian Pharmacopoeia Mac | Conkey ag | ar has |
| (1) | malachite green | (2) | bromocresol purple |
| (3) | neutral red | (4) | brilliant green |
| | pavailability and pharmacokine armaceutical companies submit | etic data | either is or may be required when |
| I. | New drug application | | |
| II. | Abbreviated new drug applica | tion | |
| III | . Supplemental application | | |
| (1) | I, II and III | (2) | I and II only |
| (3) | III only | (4) | I only |
| 47. Ga | stric emptying is slowed by all | of the follo | wing, except |
| | | | |
| (1) | fatty food | (2) | emotional stress |

| | | | | 5 |
|------------|--------------|---|----------|---|
| RRM | | | 12 | r intra venous injection |
| 48. | A sı | uspension is <i>not</i> a suitable dosage | form fo | r Total |
| | (1) | intra muscular injection | (2) | intra venous injection |
| | (3) | intra articular injection | (4) | intra dermal injection |
| 49. | Hyp to th | • | l by ga | uge numbers. The gauge number refers |
| | (1) | bevel size | | |
| | (2) | internal diameter of the cannula | | |
| | (3) | external diameter of the cannula | | × . |
| | (4) | size of the lumen opening | | |
| 50. | | mg of aspirin is to be filled in ha | ırd gela | atin capsules. Which is the appropriate |
| | (1) | 1 | (2) | 2 |
| | (3) | 0 | (4) | 00 |
| 51. | The | phase inversion temperature (PIT | of a s | urfactant is one at which |
| | (1) | surfactant forms micelles | | |
| | (2) | surfactant melts | | |
| | (3) | hydrophilic and lipophilic propert | ies of s | urfactant are balanced |
| | (4) | surfactant undergoes inversion | _ | |
| 52. | Irre | spective of the source, principle co | nstituer | nt of absorbable catgut is |
| | (1) | Cellulose | (2) | Fibrin |
| | (3) | Collagen | (4) | Gelatin |
| 53. | Idio | syncratic reactions to drugs are | | |
| | (1) | seen only in certain individuals | | |
| | (2) | unrelated with dose of drug admi | nistere | d |
| | (3) | often without explanation of caus | e | |
| | (4) | All of the above | | • |

| | | | | S |
|-------------|------|---|----------|--|
| A | | | 13 | ade |
| 54. | Wh | at is the shelf life of eye drops imm | nediatel | y after opening ? |
| | (1) | 30 days | (2) | 90 days |
| | (3) | 14 days | (4) | y after opening? 90 days 7 days rchase and distribution of 'controlled |
| 55. | | the hospitals, the records regard stances' are to be kept in prescribe | | |
| | (1) | Store keeper | (2) | Pharmacist |
| | (3) | Ward nurse | (4) | All of the above |
| 56. | In t | he test for sterility 'Fluid Thioglyco | olate M | edium' is used for detection of |
| | (1) | Aerobic bacteria | (2) | Fungi |
| | (3) | Aerobic and anaerobic bacteria | (4) | Fungi and anaerobic bacteria |
| 57. | | words "It is dangerous to take this be found on label of drugs belonging | | ation except under medical supervision" |
| | (1) | Schedule X | (2) | Schedule H |
| | (3) | Schedule C | (4) | Schedule G |
| 58. | Exc | ipients that increase the aqueous s | olubilit | y of poorly soluble drug are |
| | (1) | Wetting agents | (2) | Solubilizers |
| | (3) | Stabilizing agents | (4) | Dispersing agents |
| 59 . | Wha | at should be the air velocity in a ho | orizonta | al laminar flow work area ? |
| | (1) | 50 ft/min | (2) | 10 ft/min |
| | (3) | 200 ft/min | (4) | 100 ft/min |
| 60. | | • • | | ne used in the preparation of 250 ml of 25% w/v of anhydrous dextrose? |
| | (1) | 4.5 gms | (2) | 1·125 gms |
| | (3) | 2·5 gms | (4) | 0.9 gms |

| 61. | Whi | ich of the following can aggr | avate pain in | Prinzmetal variant angil |
|-------------|-----|-------------------------------------|-----------------|---|
| | (1) | Vasodilators | (2) | Calcium channel antagonist |
| | (3) | β blockers | (4) | Prinzmetal variant angin Calcium channel antagonist None of the above |
| 62 . | Ant | ihypertensive found safer du | ıring pregnand | • |
| | (1) | Reserpine | (2) | Propranolol |
| | (3) | Losartan | (4) | Hydralazine |
| 63. | Нур | polipidemic drug which prod | uces its effect | by inhibiting VLDL production is |
| | (1) | Lovastatin | (2) | Nicotinic acid |
| | (3) | Gemfibrozil | (4) | Fluvastatin |
| 64. | Din | nercaprol is a therapeutic an | tidote against | |
| | (1) | Heavy metals poisoning | (2) | Opiate poisoning |
| | (3) | Salicylate poisoning | (4) | Pesticide poisoning |
| 65. | Wh | ich measure is <i>not</i> used in r | nethanol poisc | oning ? |
| | (1) | Folate therapy | (2) | Sodium bicarbonate infusion |
| | (3) | Ethanol administration | (4) | Disulfiram therapy |
| 66. | The | e drug used in the first line | therapy of tub | erculosis is |
| | (1) | Ethionamide | (2) | Ethambutol |
| | (3) | Cycloserine | . (4) | Clofazimine |
| 67. | The | e reactive electrophilic i | ntermediate | of Acetaminophen which produces |
| | (1) | N-acetyl-para-benzoquinon | imine | |
| | (2) | N-acetyl-ortho-benzoquino | nimine | |
| | (3) | N-methyl-ortho-benzoquine | onimine | |
| | (4) | N-methyl-para-benzoquino | nimine | |

| | | | J.E |
|------------|---|--|--|
| | | 15 | |
| | = | been explo | nited in the prophylactic treatment Rofecoxib Nimesulide |
| (1) | Indomethacin | (2) | Rofecoxib |
| (3) | Aspirin | (4) | Nimesulide |
| Isor | niazid produces antimycobacteri | al action b | |
| (1) | inhibiting DNA dependent RN | IA polymer | rase |
| (2) | preventing bacterial protein s | ynthesis | |
| (3) | inhibiting synthesis of mycolic | acids | |
| (4) | inhibiting mycobacterial arabi | nosyl tran | sferases |
| Ant | i-HIV drug Saquinavir is | | |
| (1) | protease activator | | |
| (2) | nucleoside reverse transcripta | se inhibito | r |
| (3) | protease inhibitor | | |
| (4) | non-nucleoside reverse transcr | riptase inh | ibitor |
| Hur | nan immunodeficiency virus ca | n be trans | mitted by the following routes: |
| (1) | Blood transfusion | (2) | Placental transfer |
| (3) | Option (1) and (2) above | (4) | None of the above |
| Suci | ralfate is used in the treatment | t of | |
| (1) | Hypertension | (2) | Allergy |
| (3) | Diabetes | (4) | Ulcers |
| | · | | |
| Whi | ch of the following is systemic | antacid ? | |
| Whi | ch of the following is systemic Sodium hydroxide | antacid ? | Aluminium hydroxide |
| | (1) (3) Isor (1) (2) (3) (4) Ant (1) (2) (3) (4) Hur (1) (3) Suc: (1) | thromboembolic disorders is (1) Indomethacin (3) Aspirin Isoniazid produces antimycobacteria (1) inhibiting DNA dependent RN (2) preventing bacterial protein sy (3) inhibiting synthesis of mycolic (4) inhibiting mycobacterial arabit Anti-HIV drug Saquinavir is (1) protease activator (2) nucleoside reverse transcripta (3) protease inhibitor (4) non-nucleoside reverse transcripta (1) Blood transfusion (3) Option (1) and (2) above Sucralfate is used in the treatment (1) Hypertension | The drug whose side effect has been exploit thromboembolic disorders is (1) Indomethacin (2) (3) Aspirin (4) Isoniazid produces antimycobacterial action by the inhibiting DNA dependent RNA polymer (2) preventing bacterial protein synthesis (3) inhibiting synthesis of mycolic acids (4) inhibiting mycobacterial arabinosyl transformation. Anti-HIV drug Saquinavir is (1) protease activator (2) nucleoside reverse transcriptase inhibitor (3) protease inhibitor (4) non-nucleoside reverse transcriptase inhibitor (4) non-nucleoside reverse transcriptase inhibitor (5) Detail and (6) Detail and (7) Detail and (8) Detail a |

| 74. | Cep | halosporins produce their antibac | terial ac | tivity by interfering with |
|-------------|-----|---|-----------|---|
| | (1) | Cell wall synthesis | (2) | Cell membrane functions |
| | (3) | Ribosomal protein synthesis | (4) | tivity by interfering with Cell membrane functions Intermediary metabolic pathway |
| 75 . | The | non-sedating antihistaminic is | | |
| | (1) | Terfenadine | (2) | Diphenylhydrazine |
| | (3) | Meclizine | (4) | Mepyramine |
| 76. | Whi | ich of the following is a competitiv | ve antag | onist of H ₂ receptors ? |
| | (1) | Chlorpheniramine | (2) | Ranitidine |
| | (3) | Promethazine | (4) | All of the above |
| 77. | Whi | ich of the following agents is not | a pestici | de ? |
| | (1) | Organophosphates | (2) | Pyrethroids |
| | (3) | Aromatic hydrocarbons | (4) | Rotenone |
| 78. | Tra | zodone is used as | | |
| | (1) | Antidepressant | (2) | Antidiabetic |
| | (3) | Antiulcer | (4) | Cardiotonic |
| 79. | Sho | ck, an acute cardiovascular syndr | ome, is a | associated with |
| | (1) | Hypotension | (2) | Oliguria |
| | (3) | Metabolic acidosis | (4) | All of the above |
| 80. | βbl | ockers must be used with great ca | aution in | n diabetic patients because |
| | (1) | they mask the symptoms of hyp | oglycemi | ia |
| | (2) | they prevent the correction of hy | | |
| | (3) | Option (1) and (2) above | | |
| | (4) | None of the above | | , |

| | | | | 3 |
|-----|----------|---|---------|--|
| À | | | 17 | ade |
| 81. | | ich of the following drugs impro- uced angina? | ves exe | rcise tolerance in patients with en Metoprolol None of the above |
| | (1) | Nicardipine | (2) | Metoprolol |
| | (3) | Option (1) and (2) above | (4) | None of the above |
| 82. | Nep | hrotoxicity is common with | | |
| | (1) | Cyclosporine | (2) | Gentamicin |
| | (3) | Option (1) and (2) above | (4) | None of the above |
| | bite (1) | ? Pancuronium | (2) | d-tubocurare |
| 83. | | | revers | se the muscle paralysis following cobra |
| | (3) | Option (1) and (2) above | (4) | Edrophonium |
| 84. | | ch of the following category ertension? | of dru | ngs is not used in the treatment of |
| | (1) | Catecholamines | (2) | β receptor antagonists |
| | (3) | Potassium channel activators | (4) | Diuretics |
| 85. | βla | ctamase resistant penicillin is | | |
| | (1) | Ampicillin | (2) | Piperacillin |
| | | | | |
| | (3) | Nafcillin | (4) | Ticarcillin |
| 86. | Whi | <u>_</u> | | Ticarcillin as a 'Cardiotonic' in the treatment of |
| 86. | Whi | ich of the following drugs is em | | <u> </u> |

| | | | | S | | | | |
|-----|---|--------------------------------------|-----|---|--|--|--|--|
| RRM | | 1: | 8 | Tilde A | | | | |
| 87. | The hallmark of HIV infection is | | | | | | | |
| | (1) | increase CD_3 lymphocytes | (2) | increase $\mathrm{CD_4}$ lymphocytes decrease $\mathrm{CD_3}$ lymphocytes | | | | |
| | (3) | decrease $\mathrm{CD_4}$ lymphocytes | (4) | decrease CD_3 lymphocytes | | | | |
| 88. | Diuretic which inhibits carbonic anhydrase enzyme is | | | | | | | |
| | (1) | Hydrochlorothiazide | (2) | Furosemide | | | | |
| | (3) | Spironolactone | (4) | Acetazolamide | | | | |
| 89. | Which of the following is a narrow spectrum antibiotic? | | | | | | | |
| | (1) | Tetracycline | (2) | Ampicillin | | | | |
| | (3) | Chloramphenicol | (4) | Penicillin G | | | | |
| 90. | The specific antidote used in morphine toxicity | | | | | | | |
| | (1) | Picrotoxin | (2) | Penicillamine | | | | |
| | (3) | Naloxone | (4) | Nimesulide | | | | |
| 91. | The sub-class of pesticide Strychnine is | | | | | | | |
| | (1) | Rodenticide | (2) | Insecticide | | | | |
| | (3) | Herbicide | (4) | Fungicide | | | | |
| 92. | What is the ratio of Sulfamethoxazole and Trimethoprim in Co-trimoxazole? | | | | | | | |
| | (1) | 1:20 | (2) | 20:1 | | | | |
| | (3) | 1:1 | (4) | 20:20 | | | | |
| 93. | Which of the following is a fourth generation Cephalosporin? | | | | | | | |
| | (1) | Cefaclor | (2) | Cefotaxime | | | | |
| | | | | | | | | |

(4) Cephalexin

SPACE FOR ROUGH WORK

(3)

Cefepime

À

| | · | | | 2 | | | | |
|------|---|--|------------|-------------------------------------|--------------|--|--|--|
| À | | 1 | 9 | Tude | ARBOUNTS!COM | | | |
| 94. | A d | rug used in topical therapy of burns | | | TO | | | |
| | (1) | Mafenide | (2) | Salicylic acid | THE | | | |
| | (3) | Co-trimoxazole | (4) | Acyclovir | 7. COM | | | |
| 95. | Whi | ich of the following is not a toxic eff | ect of | salicylates? | 13 | | | |
| | (1) | Tinnitus | (2) | Gastric bleeding | | | | |
| | (3) | Edema | (4) | Postural hypotension | _ | | | |
| 96. | Whi | ch of the following antibiotics does | ot a | ct on the cell membrane ? | | | | |
| | (1) | Amphotericin B | (2) | Nystatin | | | | |
| | (3) | Polymyxins | (4) | Lincomycins | | | | |
| 97. | Plur | | | | | | | |
| | (1) | Lead | (2) | Mercury | • | | | |
| | (3) | Arsenic | (4) | Barbiturates | _ | | | |
| 98. | Concurrent ingestion of antacid with tetracycline | | | | | | | |
| | (1) | forms highly absorbable complex | | | | | | |
| | (2) | forms poorly absorbable complex | | | | | | |
| | (3) enhances metabolism of tetracycline | | | | | | | |
| | (4) | has no effect on tetracycline | | | _ | | | |
| 99. | Non | -peptide orally active angiotension-1 | rece | ptor antagonist is | | | | |
| | (1) | Saralsin . | (2) | Lisinopril | | | | |
| | (3) | Losartan | (4) | Enalapril | _ | | | |
| 100. | The | confirmatory test for positive ELISA | \ use | d the screening of HIV infection is | | | | |
| | (1) | PCR | (2) | RT-PCR | | | | |
| | (3) | Northern blot | (4) | Western blot | | | | |

SPACE FOR ROUGH WORK

सूचना - (पृष्ठ 1 वरुन पुढे....)

- Student Bounty.com प्रश्नपुस्तिकेमध्ये विहित केलेल्या विशिष्ट जागीच कच्चे काम (रफ वर्क) करावे. प्रश्नपुस्तिकेव्य उत्तरपत्रिकेवर वा इतर कागदावर कच्चे काम केल्यास ते कॉपी करण्याच्या उद्देशाने केले आहे, असे मा जाईल व त्यानुसार उमेदवारावर शासनाने जारी केलेल्या ''परीक्षांमध्ये होणाऱ्या गैरप्रकारांना प्रतिबंधे करण्याबाबतचे अधिनियम-82'' यातील तरत्दीनुसार कारवाई करण्यात येईल व दोषी व्यक्ती कमाल एक वर्षाच्या कारावासाच्या आणि/किंवा रुपये एक हजार रकमेच्या दंडाच्या शिक्षेस पात्र होईल.
- सदर प्रश्नपत्रिकेसाठी आयोगाने विहित केलेली वेळ संपल्यानंतर उमेदवाराला ही प्रश्नप्स्तिका स्वतः बरोबर (9)परीक्षाकक्षाबाहेर घेऊन जाण्यास परवानगी आहे. मात्र परीक्षा कक्षाबाहेर जाण्यापूर्वी उमेदवाराने आपल्या उत्तरपत्रिकेचा भाग-1 समवेक्षकाकडे न विसरता परत करणे आवश्यक आहे.

नमुना प्रश्न

Pick out the correct word to fill in the blank:

- Q. No. 201. The Catch varies inversely with the size of the
 - (1) nozzle
- (2) droplet
- (3) obstruction
- (4) sprayer

ह्या प्रश्नाचे योग्य उत्तर "(3) obstruction" असे आहे. त्यामुळे या प्रश्नाचे उत्तर "(3)" होईल. यास्तव खालीलप्रमाणे प्र.क्र. 201 समोरील उत्तर-क्रमांक "③" हे वर्तुळ पूर्णपणे छायांकित करून दाखविणे आवश्यक आहे.

प्रश्न क्र. 201. (1) (2)

अशा पद्धतीने प्रस्तुत प्रश्नपुस्तिकेतील प्रत्येक प्रश्नाचा तुमचा उत्तरक्रमांक हा तुम्हाला स्वतंत्ररीत्या प्रविलेल्या उत्तरपत्रिकेवरील त्या त्या प्रश्नक्रमांकासमोरील संबंधित वर्तुळ पूर्णपणे छायांकित करून दाखवावा. ह्याकरिता फक्त काळ्या शाईचे बॉलपेन वापरावे, पेन्सिल वा शाईचे पेन वापरू नये.

कच्च्या कामासाठी जागा / SPACE FOR ROUGH WORK